Yield10 Bioscience Inc
NASDAQ:YTEN
Intrinsic Value
The intrinsic value of one
YTEN
stock under the Base Case scenario is
2.2
USD.
Compared to the current market price of 2.5 USD,
Yield10 Bioscience Inc
is
Overvalued by 12%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
YTEN Profitability Score
Profitability Due Diligence
Yield10 Bioscience Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Yield10 Bioscience Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
YTEN Solvency Score
Solvency Due Diligence
Yield10 Bioscience Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Yield10 Bioscience Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Yield10 Bioscience Inc
| Current Assets | 5M |
| Cash & Short-Term Investments | 4.3M |
| Receivables | 30k |
| Other Current Assets | 641k |
| Non-Current Assets | 3.1M |
| PP&E | 2.7M |
| Other Non-Current Assets | 331k |
| Current Liabilities | 1.6M |
| Accounts Payable | 109k |
| Accrued Liabilities | 1.5M |
| Non-Current Liabilities | 2.1M |
| Other Non-Current Liabilities | 2.1M |
YTEN Capital Structure
Yield10 Bioscience Inc
| Market Capitalization | 12.2M USD | |
| Total Debt | 0 USD | |
| Minority Interest | 0 USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 2.4M USD | |
| Short-Term Investments | 2M USD | |
| Enterprise Value | 7.9M USD | |
Wall St
Price Targets
YTEN Price Targets Summary
Yield10 Bioscience Inc
According to Wall Street analysts, the average 1-year price target for
YTEN
is 14.96 USD
with a low forecast of 7.07 USD and a high forecast of 26.25 USD.
Ownership
YTEN Insider Trading
Buy and sell transactions by insiders
During the last 12 months Yield10 Bioscience Inc insiders bought 16.8k USD , and have not sold any shares. The last transaction was made on Mar 25, 2023 by Sinskey Anthony J (Director), who bought 5.6k USD worth of YTEN shares.
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
N/A
|
N/A
|
N/A |
| 6 Months |
N/A
|
N/A
|
N/A |
| 9 Months |
N/A
|
16.8k
USD
|
16.8k
|
| 12 Months |
N/A
|
16.8k
USD
|
16.8k
|
Shareholder Return
YTEN Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
YTEN Price
Yield10 Bioscience Inc
| Average Annual Return | -42.97% |
| Standard Deviation of Annual Returns | 30.65% |
| Max Drawdown | -98% |
| Market Capitalization | 12.2M USD |
| Shares Outstanding | 5 074 090 |
| Percentage of Shares Shorted | 1.56% |
Company Profile
Yield10 Bioscience Inc
Country
Industry
Market Cap
Dividend Yield
Description
Yield10 Bioscience, Inc. operates as an agricultural bioscience company. The company is headquartered in Woburn, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2006-11-10. The firm is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low-carbon sustainable seed products. The firm focuses on petroleum replacement markets, in which it is developing Camelina oil for use as a biofuel feedstock and polyhydroxyalkanoates (PHA) bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and food and nutrition markets, in which it is developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets. The company is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits that form improved elite Camelina varieties for the biofuel market. The firm's new seed product traits include the PHA bioplastic trait developed by the Company and the omega-3 (DHA+EPA) oil traits.
Contact
IPO
Employees
Officers
The intrinsic value of one
YTEN
stock under the Base Case scenario is
2.2
USD.
Compared to the current market price of 2.5 USD,
Yield10 Bioscience Inc
is
Overvalued by 12%.
